What is the clinical evidence from this study?

Study design: Review. Population: Von Willebrand disease. Intervention: Von Willebrand disease care and diagnosis.

What question did this study set out to answer?

To review current clinical frameworks, diagnostic innovations, and evolving therapeutic strategies for managing von Willebrand disease across Nordic comprehensive care centers.

January 15, 2018Annals of BloodOpen Access

Von Willebrand disease—the Nordic perspective

View Full Paper

Ask AI

Bookmark

Key result

Von Willebrand disease affects up to 4 per 100,000 Nordic residents amid evolving VWF concentrate therapies.

Population

Patients with Von Willebrand disease in Nordic countries

Design

Review

Authors

TSTímea SzántóUniversity of Helsinki RLRiitta LassilaUniversity of Helsinki EFEva FundingUniversity of Copenhagen

Discussion

Member takes

Implication

VWD prevalence varies regionally; leaves open need for harmonized diagnostic thresholds in multinational studies.

Key Points

To review current clinical frameworks, diagnostic innovations, and evolving therapeutic strategies for managing von Willebrand disease across Nordic comprehensive care centers.
Synthesized diagnostic and clinical management guidelines established by the Nordic Haemophilia Council.
Evaluated standardized diagnostic protocols incorporating bleeding scores, traditional laboratory analyses, and whole-blood platelet function testing.
Reported disease prevalence ranges from 0.2 to 4 cases per 100,000 inhabitants for type 2 and 0.2 to 1 case per 100,000 for type 3 across Nordic countries.
Biological activity of von Willebrand factor does not consistently align with clinical bleeding severity, underscoring the necessity of multi-modal classification.
Clinical management is advancing through the implementation of pure von Willebrand factor concentrates, refined factor activity assays, and global coagulation monitoring.

Structured PICO

Population

Patients with Von Willebrand disease in Nordic countries

Exposure

Diagnosis and clinical management including pure von Willebrand factor (VWF) concentrates and novel laboratory assays

This review provides an overview of the current diagnostic and therapeutic landscape for Von Willebrand disease in the Nordic countries.

Cite This Study

Szántó et al. (2018) conducted a review in Von Willebrand disease. Von Willebrand disease care and diagnosis was evaluated. Von Willebrand disease has a prevalence of 0.2 to 4 cases per 100,000 for type 2 and 0.2 to 1 for type 3 in the Nordic countries, with evolving diagnostic assays and pure VWF concentrate treatments.

synapsesocial.com/papers/6aa148f17ead44eb96777813 https://doi.org/10.21037/aob.2017.12.07

View Full Paper

Ask AI

Bookmark

Von Willebrand disease—the Nordic perspective

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Von Willebrand disease—the Nordic perspective

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider